Multiple genetic alterations are required to induce acute myelogenous leukemia (AML).
Introduction
Acute myelogenous leukemia (AML) is a complex disease that is classified by histochemical, cytochemical and genetic markers. Genetic alterations affecting members of the core binding factor (CBF), a heterodimeric transcription factor, are some of the most common events in AML and define a large group commonly designated CBF-AML, 1 which includes patients with either t(8;21) or inv (16) . Evidence from experimental studies support the hypothesis that these fusion proteins impair myeloid differentiation and/or expand a hematopoietic stem/progenitor cell pool, but are insufficient to cause leukemia. [2] [3] [4] [5] [6] Secondary genetic alterations, such as mutations in receptor tyrosine kinases (RTK), are thus required for induction of an overt AML. Although the KIT receptor is expressed on the majority of AML blasts, mutations in the KIT gene are exclusively associated with CBF-AML. [7] [8] [9] [10] [11] In addition to mutations affecting D816 within the KIT tyrosine kinase domain 2 (TK2), complex insertion/deletion mutations in exon8 affecting the extracellular (EC) domain are also observed in CBF-AML, with an especially high prevalence (26%) in inv(16) patients, and which correlates with a higher risk of relapse. 8, 9 In addition to EC mutations, a mutation in the transmembrane (TM) domain (V530I) has also been described in CBF-AML. 9, 11 Previous studies have shown that the KIT D816V mutation induces growth-factor independent growth of myeloid and mast cells and is insensitive to the RTK inhibitor imatinib mesylate. [12] [13] [14] The purpose of this study was to test the functional activity of the EC and TM KIT mutations associated with CBF-AML, to determine their sensitivity to imatinib, and to delineate the activated signaling pathways.
Study design
Site-directed mutagenesis was used to create KIT mutants from either murine or human KIT cDNAs, as indicated in Table 1 . KIT mutants were cloned into the SF91 retroviral vector coexpressing the yellow fluorescence protein (YFP), which were used to infect FDC-P1 cells in 
Results and Discussion
To analyze the oncogenic potential of KIT mutations that have been identified in CBF-AML, a series of KIT mutants were tested for their ability to stimulate proliferation and inhibit apoptosis of myeloid cells. Firstly, two KIT mutants were generated that have been cloned from patients with AML, 9 one with a V530I substitution in the TM domain and a second with a complex deletion / insertion mutation affecting the EC domain (T417∆,Y418∆,D419∆,InsV; designated "exon8"). As all EC in-frame deletion plus insertion mutations observed in AML lead to the loss of the evolutionary highly conserved amino acid D419, 9 we also created a mutant (D419A), in which the acidic Asp is replaced with the neutral hydrophobic Ala. This mutant directly tests if loss of D419 is the critical mutation in these mutants. As a positive control for growth stimulation, we used the TK2 mutants hD816V and mD814V and the juxtamembrane (JX) mutant mV558D, identified in mastocytosis and gastro-intestinal-stroma tumors (GIST). 15, 16 These mutants also served as negative (mD814V/hD816V) and positive (mV558D) controls for the response to imatinib. 17 Expression of each of the KIT mutants in IL3-dependent FDC-P1 cells lead to factorindependent growth under stringent conditions, but with different efficiencies (Table 1) .
Whereas the TK2 and JX mutants gave rise to factor-independent cells at a frequency between 10 -2 and 10 -3
, the frequency was two to three orders of magnitude lower for EC and TM The frequency to IL3 independent growth was calculated by end-point dilution of infected cells plated in the absence of IL3 and applying the Poisson distribution. 25 The frequency was corrected for the plating efficiency in IL3 for each culture (between 42% and 96%). In two independent experiments, in which 10 7 cells were plated in the absence of IL3, no factorindependent growth was observed in FDC-P1 expressing the control vector or wt hKIT. The frequency of obtaining cell growth in hSCF (100 ng/ml) was determined in FDC-P1 cells infected with the wt hKIT vector. The exact incidence of factor-independent growth was not determined for mutant V530I, but is between 7 x 10 -6 and 5 x 10 -5 .
mutants. Importantly, no spontaneous factor-independent growth was observed in control infected FDC-P1 cells expressing YFP alone or wild-type KIT, supporting the conclusion that expression of the EC and TM KIT mutants were responsible for the factor-independent growth. The low frequency of obtaining factor-independent growth with these mutants relative to the JX and TK2 mutations may reflect the necessity of high KIT expression levels.
This hypothesis is supported by the fact that the transcription levels of the vectors (as
by YFP expression) was three-to six-fold higher in IL3-independent cultures expressing EC and TM mutants, as compared to the other mutants ( Figure 1A ). This was further documented by Western blot analysis in which KIT protein levels were examined, which correlated well with YFP expression levels ( Figure 1B) , although a direct comparison is complicated by potential differences in receptor turnover rates. Notably, all cultures proliferated at comparable rates and no significant difference in proliferation rates were observed if IL3 was added to the cultures, demonstrating optimal cell growth in the selected cultures (data not shown).
To determine if the EC and TM mutants are sensitive to RTK inhibitors, we tested the effect of imatinib on the factor-independent growth of FDC-P1 cells expressing the KIT mutants in proliferation assays. Under pharmacological doses of imatinib, FDC-P1 cultures expressing EC and TM mutants showed a drastic reduction in proliferation ( Figure 1C ), which could be rescued by addition of IL3 (data not shown). The IC 50 dose required for these mutants was lower (0.1µM) than that for wt KIT stimulated with the KIT ligand (0.5µM), but was similar to that required for V558D mutants, commonly observed in imatinib-responsive GIST patients. 17 The inhibition of V530I is consistent with recent results with another TM mutant (F522C) identified in mastocytosis. 18 Inhibition of EC and TM mutant KIT activity not only abrogated proliferation, but induced high frequencies of apoptosis, as detected by Annexin V staining ( Figure 1D ). Figure 1F) . Strikingly, the PI3K-inhibitor LY294002 reduced proliferation rates of FDC-P1 cells expressing either the EC or JX KIT mutants to levels similar to that observed by directly inhibiting the KIT receptor using imatinib, in contrast to the MAPKinhibitor PD98059, which only partially inhibited proliferation. Indeed, the PI3K inhibitor was alone sufficient to inhibit proliferation of the TK2 KIT mutants, resistant to imatinib.
Rapamycin, which inhibits the AKT downstream effector mTOR, only partially inhibited proliferation, underlining the importance of other known downstream effectors of PI3K-AKT.
In summary, we show that both the EC (exon8) and TM mutants, which are found in CBF-AMLs at a high frequency, lead to constitutive activation of KIT. Furthermore, our data demonstrate that disruption of Asp419 is the critical event in EC mutations. Both the low transforming frequency in our assay, as well as their exclusive association with CBF-AMLs, suggest that high KIT expression levels or other secondary cooperating events may be a prerequisite for the transforming properties of EC or TM mutations. Interestingly, a recent study has shown that the fusion protein generated by t(8;21) induces high KIT expression levels in U937 cells. 10 The striking responsiveness of both EC and TM KIT mutants to 
